Authors

Latest:

Dr. Cheng Discusses RICTOR Amplification in Lung Cancer

Haiying Cheng, MD, medical oncologist, Montefiore Einstein Center for Cancer Care, assistant professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, discuses RICTOR amplification in patients with lung cancer.

Hak Choy, MD

Latest:

Dr. Choy Discusses Therapy for Oligometastatic Lung Cancer

Hak Choy, MD, Nancy B. & Jake L. Hamon Distinguished Chair in Therapeutic Oncology Research, Department of Radiation Oncology, UT Southwestern Medical Center, discuses therapy for patients with oligometastatic lung cancer.

Halle Moore, MD

Latest:

Dr. Moore on the Use of Preventive Anastrozole Versus Tamoxifen in DCIS

Halle Moore, MD, discusses the use of preventive anastrozole versus tamoxifen in ductal carcinoma in situ.

Hanmath J Neboori, MD

Latest:

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Hannah Kent-Ritchie, PhD

Latest:

Experts Give Advice on How to Plan a Successful Lung Cancer Screening Program

Screening high-risk individuals for lung cancer with low-dose tomography is an effective and recommended approach for reducing mortality from the condition. That said, planning a lung cancer screening program can be challenging, as a successful program requires strategic multidisciplinary.

Hannah Slater

Latest:

Paving the Way to Modern Cancer Therapy

When George P. Canellos, MD, first joined the field of oncology in the 1960s, many of his peers thought he was making huge mistake.

Hanneke Poort, PhD

Latest:

Addressing Fatigue as an Adverse Event in Ovarian and Uterine Cancers

Hanneke Poort, PhD, discusses research regarding fatigue as an adverse event in patients with gynecologic cancer.

Hans-Christian Kolberg, MD

Latest:

Dr. Kolberg on Collecting Real-World Biosimilar Trastuzumab Data in Breast Cancer

Hans-Christian Kolberg, MD, discusses collecting real-world data for biosimilars, specifically the trastuzumab biosimilar ABP 980 for breast cancer.

Hans Hammers, MD, PhD

Latest:

Data Updates in Advanced RCC from 2023 IKCS: North America

Drs Rini and Hammers discuss additional clinical readouts from the 2023 IKCS: North America meeting including emerging agents for advanced RCC such as belzutifan and zanzalitinib.

Hans J. Hammers, MD, PhD, UT Southwestern Medical Center

Latest:

Scenario 3: A 44-Year-Old Woman With RCC at Intermediate-High Risk for Recurrence

Expert panelists highlight aspects of a final patient scenario, discussing adjuvant treatment strategies in the setting of renal cell carcinoma at intermediate-high risk for recurrence.

Hans-Joachim Schmoll, MD

Latest:

Dr. Schmoll on the Toxicity of the CHARTA Study in CRC

Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/Oncology, University Hospital Halle, discusses the toxicity of the CHARTA study for patients with colorectal cancer (CRC).

Haralambos Raftopoulos, MD

Latest:

Dr. Raftopoulos on Pulmonary Toxicity With EGFR TKIs

Haralambos Raftopoulos, MD, associate professor, Hofstra North Shore-LIJ School of Medicine, discusses pulmonary toxicity with EGFR tyrosine kinase inhibitors (TKIs).

Harikrishna Nakshatri, BVSc, PhD

Latest:

Dr Nakshatri on the Investigation of TONSL in Breast Cancers

Harikrishna Nakshatri, BVSc, PhD, discusses the investigation of TONSL in patients with breast cancer.

Harold A. Harvey, MD

Latest:

Dr. Harvey Discusses Preventing Breast Cancer

Dr. Harold Harvey from Penn State Hershey Cancer Institute Discusses Preventing Breast Cancer

Harold Burstein, MD, PhD

Latest:

Addressing Unmet Needs in HR+/HER2- Metastatic Breast Cancer

Before closing out their discussion on CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, experts highlight remaining unmet needs in this setting.

Harold J. Burstein, MD, PhD

Latest:

Dr. Burstein on the Treatment Landscape of HER2+ Breast Cancer

Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the treatment landscape of HER2-positive breast cancer.

Harold J. Burstein, MD, PhD, Dana-Farber

Harold J. Burstein, MD, PhD, Dana-Farber&nbsp

Harold J. Burstein, MD, PhD, Dana-FarberÂ

Harold J. Burstein, MD, PhD, Harvard Medical School